Asian Investment Conference 2022
Founder and CEO, Insilico Medicine
Alex Zhavoronkov is Founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics and the Biogerontology Research Foundation.
Dr. Zhavoronkov also used to be a GPU-technology expert and was listed among the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare by Deep Knowledge Analytics.
Dr. Zhavoronkov has been inventing critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for the generation of novel molecular structures with desired properties and the generation of synthetic biological and patient data, since 2015. He also pioneered the application of deep learning technologies for the prediction of human biological age using multiple data types, transferring learning from aging into disease, target identification, and signaling pathway modeling.
Since 2012, Dr. Zhavoronkov has published over 150 peer-reviewed research papers, and two books.
Dr. Zhavoronkov has a Bachelor degree with Honors in Finance and Management of Information Systems, as well as a Bachelor of Science degree in Computer Science. He also holds a Master of Science degree in Biotechnology from The John Hopkins University and a Ph.D. degree in Physics.